Suchergebnisse - "De Giorgi, Ugo"

PubPharm (33)

1

Enzalutamide and leuprolide acetate in non-metastatic hormone-sensitive prostate cancer : the sooner the better?

enthalten in: Future oncology (London, England) | 2024

von Giunta, E. | Gasperoni, L. | De Giorgi, U.

2

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer : the phase 3 TALAPRO-2 trial

enthalten in: Nature medicine | 2024

von Fizazi, K. | Azad, A. | Matsubara, N. | +18

ErratumIn: Nat Med. 2024 Jan 31;:. - PMID 38297094

3

Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer

enthalten in: NEJM evidence | 2023

von Freedland, S. | Gleave, M. | De Giorgi, U. | +14

4

Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer

enthalten in: The New England journal of medicine | 2023

von Freedland, S. | de Almeida Luz, M. | De Giorgi, U. | +17

CommentIn: N Engl J Med. 2024 Jan 4;390(1):90. - PMID 38169497

5

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2) : a randomised, placebo-controlled, phase 3 trial

enthalten in: Lancet (London, England) | 2023

von Agarwal, N. | Azad, A. | Carles, J. | +18

CommentIn: Lancet. 2023 Jul 22;402(10398):266-267. - PMID 37285866

6

A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

enthalten in: The Prostate | 2023

von Fernandez-Perez, M. | Perez-Navarro, E. | Alonso-Gordoa, T. | +28

7

Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes : A Post Hoc Analysis of the PROSPER Randomized Clinical Trial

enthalten in: The Journal of urology | 2023

von Hussain, M. | Sternberg, C. | Efstathiou, E. | +9

8

Rucaparib or Physician's Choice in Metastatic Prostate Cancer

enthalten in: The New England journal of medicine | 2023

von Fizazi, K. | Piulats, J. | Reaume, M. | +126

CommentIn: Nat Rev Urol. 2023 Apr;20(4):199. - PMID 36928618

9

Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

enthalten in: Journal of translational medicine | 2023

von Nuzzo, P. | Pederzoli, F. | Saieva, C. | +16

10

Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?

enthalten in: Future oncology (London, England) | 2022

von De Giorgi, U. | Hussain, M. | Shore, N. | +11

CommentOn: Eur J Cancer. 2021 Dec;159:237-246. - PMID 34784577